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, Amelia Hochreiter-Hufford 1, 2, 3 , Larry Borish 1, 4, 6 & Kodi S. Ravichandran 1, 2, 3 Lung epithelial cells can influence immune responses to airway allergens 1, 2 . Airway epithelial cells also undergo apoptosis after encountering environmental allergens 3 ; yet, relatively little is known about how these are cleared, and their effect on airway inflammation. Here we show that airway epithelial cells efficiently engulf apoptotic epithelial cells and secrete anti-inflammatory cytokines, dependent upon intracellular signalling by the small GTPase Rac1. Inducible deletion of Rac1 expression specifically in airway epithelial cells in a mouse model resulted in defective engulfment by epithelial cells and aberrant anti-inflammatory cytokine production. Intranasal priming and challenge of these mice with house dust mite extract or ovalbumin as allergens led to exacerbated inflammation, augmented Th2 cytokines and airway hyper-responsiveness, with decreased interleukin (IL)-10 in bronchial lavages. Rac1-deficient epithelial cells produced much higher IL-33 upon allergen or apoptotic cell encounter, with increased numbers of nuocyte-like cells 1, 4, 5 . Administration of exogenous IL-10 'rescued' the airway inflammation phenotype in Rac1-deficient mice, with decreased IL-33. Collectively, these genetic and functional studies suggest a new role for Rac1-dependent engulfment by airway epithelial cells and in establishing the anti-inflammatory environment, and that defects in cell clearance in the airways could contribute to inflammatory responses towards common allergens.
Exposure to environmental pollutants, allergens and pathogens can induce apoptosis of airway epithelial cells 3, 6, 4, 7 . In fact, clusters of uncleared epithelial cells referred to as 'Creola bodies' in the sputum have been seen in patients with asthma for decades 8, 9 . Although the lung contains professional phagocytes such as macrophages and dendritic cells, many so-called 'non-professional phagocytes' can engulf apoptotic cells 10, 11 . Because the bronchial epithelial cells come in contact with allergens first, and greatly outnumber the professional phagocytes in situ, we asked whether epithelial cells might contribute to cell clearance in the airways.
We tested phagocytosis by primary murine airway epithelial cells, the human bronchial epithelial cell line BEAS-2B and the murine alveolar epithelial cell line MLE-12. To score internalization, we labelled the apoptotic epithelial cells with a pH-dependent dye (CypHer5), whose fluorescence increased within acidic phagolysosomes 12, 13 ( Fig. 1a, b) . BEAS-2B, MLE-12 and the primary murine airway epithelial cells (CD45 2 EpCAM 1 ) engulfed apoptotic targets; this was dependent on phosphatidylserine (PtdSer) recognition on the apoptotic cells (inhibitable by annexin V) (Fig. 1b) . Apoptotic cell recognition by professional phagocytes is known to elicit anti-inflammatory mediators that dampen inflammation in the local tissue environment 14, 15 . Airway epithelial cells also produced active transforming growth factor (TGF)-b and PGE 2 after apoptotic cell recognition, and dependent on phosphatidylserine and Rac1 (Fig. 1c, d and Supplementary Fig. 1a,  b ). This suggests that airway epithelial cells can engulf apoptotic targets and produce anti-inflammatory mediators.
To test the importance of cell clearance by airway epithelial cells in vivo, we wished to delete engulfment genes specifically within epithelial cells and assess airway inflammation. Because phagocytes often express several engulfment receptors, and the relative importance of particular engulfment receptors on the epithelial cells is not fully characterized, we targeted the small GTPase Rac1, which functions downstream of several engulfment signalling pathways 15, 16 . Deletion of Rac1 in the airway epithelial cells was achieved by crossing Rac1 fl/fl mice with clara cell secretory protein (CCSP)-rtTA / tetO -Cre transgenic mice, which express Cre under tissue-specific and temporal control ( Fig. 1e and Supplementary Fig. 2a ) 16, 17 . Doxycycline (Dox) given through drinking water induced Cre expression in the epithelial cells of the trachea, bronchi and bronchioles under the promoter for the Clara cell-specific secretory protein (CCSP) 18 ( Supplementary  Fig. 2b ). Dox administration to CCSP-Cre/Rac1 fl/fl mice led to Rac1 deletion specifically in the epithelial cells (Fig. 1f, g ), but not in other cells in the bronchial tissue, or in CD45 1 haematopoietic cells (Fig. 1f ). Rac1 expression in CCSP-Cre/Rac1 fl/fl mice was unaffected before doxycycline treatment, and Dox treatment of Rac1 wt/wt mice did not affect Rac1 or Rac2 expression.
The doxycycline-inducible system allowed the airways to develop normally, until Rac1 deletion at 8 weeks. However, because Rac1 is a key cytoskeletal regulator in many cell types, we were concerned about potential unintended effects. Several independent lines of evidence alleviated this concern. First, the architecture and epithelial cell morphology of the airways were comparable at steady state in control and Rac1 deleted mice ( Supplementary Fig. 2b ). Second, numbers of yellow fluorescent protein (YFP 1 )-expressing epithelial cells in CCSPCre/Rac1 fl/fl mice crossed to Rosa26 STOP-EYFP reporter mice were comparable to controls (Fig. 1f) ; importantly, Rac1 expression was deleted in the YFP 1 epithelial cells but not CD45 1 YFP 2 haematopoietic cells ( Fig. 1f and Supplementary Fig. 3c ). Third, primary epithelial cell cultures yielded similar total numbers of cells positive for nitrotetrazolium blue from control and CCSP-Cre/Rac1 fl/fl mice ( Supplementary  Fig. 4a ). Fourth, the epithelial cell integrity and tight junction formation was unaffected after Rac1 deletion, on the basis of staining for the tight-junction protein occludin ( Supplementary Fig. 4c, d ) and transmission electron microscopy ( Supplementary Fig. 5a ). Fifth, integrity of the alveolar-capillary membrane in CCSP-Cre/Rac1 fl/fl was intact on the basis of intravenous injection of Evan's blue and tracking the dye in the lung (Supplementary Fig. 4b ). Sixth, the uptake of intranasally administered fluorescently labelled antigens by epithelial cells, dendritic cells, and alveolar macrophages was similar between control and Rac1-deficient mice ( Supplementary Fig. 5b, c) . Collectively, Dox-induced deletion of Rac1 in the airway epithelial cells in the CCSP-Cre/Rac1 fl/fl mice did not affect the integrity of the epithelial cells. Airway epithelial cells from CCSP-Cre/Rac1 fl/fl mice showed significant reduction in phagocytosis of apoptotic cells in vitro (Fig. 1h) , and after intranasal administration of apoptotic cells in vivo ( Supplementary Fig. 6a ); in contrast, alveolar macrophages from these mice showed no phagocytic defect ( Supplementary Fig. 6b Fig. 8b ). Thus, mice lacking Rac1 in the airway epithelial cells showed defective ability to engulf apoptotic cells and altered inflammatory response in vivo.
We next tested these mice in airway inflammation models. One common approach to induce airway inflammation is to prime with antigen intraperitoneally and subsequently challenge with the same antigen by the intranasal route. We tested the development of allergic inflammation in CCSP-Cre/Rac1 fl/fl mice to low-endotoxin house dust mite (HDM) extract, a common airway allergen. The control mice showed T-cell and eosinophil infiltration, along with immunoglobulin-E (IgE) response and Th2 cytokines IL-4, IL-5 and IL-13, but all these parameters were heightened in the CCSP-Cre/Rac1 fl/fl mice (Supplementary Fig. 7 ), suggesting that losing Rac1 expression in airway epithelial cells exacerbates inflammation.
Because humans encounter environmental antigens through the airways before developing symptoms of airway inflammation, we established a system where both the primary allergen encounter and secondary challenge were through the intranasal route (Fig. 2a) . After Dox-induced Rac1 deletion followed by intranasal priming and challenge with HDM, the CCSP-Cre/Rac1 fl/fl mice showed a strong airway inflammation phenotype with significant accumulation of mucus (Fig. 2b) . In contrast, controls showed minimal or undetectable airway inflammation after intranasal priming and challenge. These control conditions included Dox-treated, saline injected CCSP-Cre/Rac1 fl/fl mice (by TdT-mediated dUTP nick end labelling and cleaved caspase 3 staining), the staining was variable between samples, probably because of mucus and other secretions in inflamed tissues (data not shown).
Allergic airway inflammation involves Th2 responses in the lungs 5, 20, 21 . The CCSP-Cre/Rac1 fl/fl mice showed high concentrations of Th2 cytokines IL-4, IL-5, IL-13, eosinophil and T-cell infiltration in BAL fluid (Fig. 2c ). IL-10 was significantly reduced in the Rac1-deficient mice (Fig. 2c) , correlating with low IL-10 seen in airways of asthmatic patients 22 . When re-stimulated with HDM ex vivo, CD4
1 T cells from the mediastinal lymph nodes of CCSP-Cre/Rac1 fl/fl mice produced much higher amounts of IL-4, IL-5 and IL-13 than control mice (Fig. 2d) . When Rac1 deletion in the airway epithelial cells was controlled (by Dox administration) at either the priming (sensitization) or challenge phases, keeping Rac1 expression normal at the priming phase and deleting at the challenge phase showed minimal airway inflammation to HDM ( Supplementary Fig. 9 ). These data suggest that Rac1 expression in airway epithelial cells plays a critical role in preventing sensitization to common airway allergens encountered by the intranasal route.
When we analysed lung function parameters, HDM-sensitized CCSP-Cre/Rac1 fl/fl mice showed physiological changes consistent with asthma including much greater airway resistance, decreased compliance and higher pulmonary arterial pressure (Fig. 2e) . Loss of Rac1 led to a twofold increase in methacholine-induced airway hyperresponsiveness compared with wild-type littermates ( Supplementary  Fig. 10 ). Thus, Rac1 expression in airway epithelial cells critically controls allergen-induced airway inflammation and the physiological changes of asthma. Interestingly, intranasal priming and challenge of the LysM-Cre/Rac1 fl/fl mice with HDM did not show enhanced airway inflammation ( Supplementary Fig. 8c, d) .
We next asked whether exogenous IL-10 could reverse the inflammatory phenotype in CCSP-Cre/Rac1 fl/fl mice. Recombinant mouse IL-10 (rIL-10) given at priming and challenge phases with HDM resulted in markedly reduced airway inflammation, manifested by reduced production of mucus (Fig. 3a, b) , and lower Th2 cytokines IL-4, IL-5 and IL-13 in the airways. The mediastinal lymph nodes were substantially smaller in the rIL-10-treated CCSP-Cre/Rac1
fl/fl mice, with a significant decrease in the HDM-induced production of Th2 
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cytokines (Fig. 3c-e) . rIL-10-treated mice also showed improved pulmonary function (Fig. 3f) . This suggests that Rac1 expression in epithelial cells and IL-10 amounts in the airways are complementary factors regulating airway inflammation.
Preparations of HDM are enriched in the type-2-group allergen Der p2, an LPS-binding protein 23, 24 . To test whether mice lacking Rac1 in the airway epithelial cells are inherently sensitive to allergen exposure in the absence of adjuvant activity, we first primed CCSP-Cre/Rac1 fl/fl mice with recombinant Der p1, which showed augmented IgE and IgG1 antibody response and increased inflammation (Supplementary Fig. 7e, f) . Second, although intranasal administration of chicken ovalbumin (Ova) without LPS often leads to tolerance induction 25 , in CCSP-Cre/Rac1 fl/fl mice intranasal priming/challenge with Ova led to airway inflammation (Fig. 4a-d) . Control mice showed minimal inflammation. Mediastinal lymph node cells from Rac1-deficient mice also produced higher IL-4, IL-5 and IL-13 (Fig. 4e) . We confirmed that control mice primed with (Ova plus alum) by the intraperitoneal route and challenged with Ova by the intranasal route showed airway inflammation ( Supplementary Fig. 11 ). In CCSP-Cre/Rac1 fl/fl mice, the amounts of IL-10 in the BAL fluid were lower after Ova priming and challenge, and administering rIL-10 significantly reduced this inflammation (Fig. 4f-h) . Thus, Rac1 loss in the bronchial epithelial cells and reduced IL-10 creates a state that is prone to inflammation in response to normally innocuous inhaled allergens.
Thymic stromal lymphopoietin (TSLP) and IL-33 represent two cytokines linked to promoting airway inflammation 1, 26, 27 . Although TSLP did increase in the BAL fluid after HDM challenge, this was comparable between control and CCSP-Cre/Rac1 fl/fl mice. However, IL-33 was significantly higher in the CCSP-Cre/Rac1 fl/fl mice after allergen challenge (although basal IL-33 without HDM challenge was not increased) (Fig. 5a ). Treatment with rIL-10 diminished the IL-33 
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amounts in the BAL fluid (Fig. 5a ). IL-33 has been implicated in the pathogenesis of many diseases including asthma 28 . Recently, IL-33 has been shown to activate and expand a non-T/non-B population of innate lymphoid cells ('nuocytes'), linked to promoting airway inflammation 27, 29 . After HDM priming, lungs from CCSP-Cre/Rac1 fl/fl mice contained significantly higher IL-5-expressing cell populations resembling nuocytes (lineage (Fig. 5b) . Interestingly, after HDM priming of CCSP-Cre/Rac1 fl/fl mice (less than 6 days), the lung nuocytes (but not CD4 1 T cells) were positive for IL-5 ( Supplementary Fig. 12a, b) , suggesting inducible nuocyte activation. A neutralizing IL-33 antibody reduced the inflammation in the CCSP-Cre/ Rac1 fl/fl mice, with reduction in lymph node cellularity, infiltrating eosinophils and activated CD4 1 T cells ( Supplementary Fig. 12c, d ). Although the function of this lung nuocyte-like population needs further testing, these data suggest a link between enhanced IL-33 production in the CCSP-Cre/Rac1 fl/fl mice after allergen challenge, the expansion of an IL-5 producing nuocyte-like population and airway inflammation.
Because epithelial cells are a main source of IL-33, we asked how Rac1 affects IL-33 expression. When MLE-12 epithelial cells were stimulated with HDM or apoptotic cells, IL-33 messenger RNA (mRNA) was upregulated; drug-mediated inhibition of Rac1 (ref. 30) or short interfering RNA (siRNA) knockdown of Rac1 led to a three-to sixfold increase in IL-33 ( Supplementary Fig. 13 and Fig. 5c ). This IL-33 mRNA upregulation due to Rac inhibition was not a generic effect, as the inhibitor greatly diminished Rac1-dependent TGF-b expression ( Supplementary Fig. 13b ).
To test whether Rac1 deletion affects IL-33 expression in primary airway epithelial cells during allergen challenge, we used the CCSP-Cre/Rac1 fl/fl mice crossed to the Rosa26 STOP-EYFP reporter mice. 
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Although the YFP 1 EpCAM 1 airway epithelial cells from control and CCSP-Cre/Rac1 fl/fl mice had comparable amounts of basal IL-33 message, this was significantly increased after HDM stimulation. Second, in the BAL fluid of Rac1-deficient mice, IL-33 cytokine was increased three-to fivefold after intranasal priming with HDM, whereas the TSLP amounts were comparable (Fig. 5d, e) . Third, after intranasal injection of apoptotic epithelial cells, purified YFP 1
EpCAM
1 epithelial cells from Rac1-deficient mice had much higher IL-33 mRNA (Fig. 5e) . This link between Rac1 and il-33 expression was also seen in human nasal epithelial cells, as production of IL-33 by HDM or apoptotic cells was strongly enhanced by Rac inhibition (Fig. 5f) . Collectively, these data suggest a critical role for Rac1 expression in epithelial cells in regulating IL-33 expression and, in turn, the sensitization to inhaled allergens.
Although airway epithelial cells are the first to come in contact with the allergens, their contribution to tolerance towards common airway allergens has been less clear. The data presented here suggest that airway epithelial cells can be phagocytic, and that their ability to secrete/modulate cytokines can critically influence tolerance to common airway allergens. Thus, apart from a physical barrier, phagocytosis in the airways may be part of an extra line of immune protection against innocuous antigens. These data also identify a new Rac-1 dependent IL-33:IL-10 axis in controlling airway inflammation. The amounts of the pro-inflammatory cytokine IL-33 and the anti-inflammatory cytokine IL-10 seem linked, with Rac1 expression in airway epithelial cells controlling both steps. Although asthmatic patients have deficits in IL-10 (ref. 22) , the contribution of IL-10 to allergen sensitization and its potential therapeutic use remains unexplored. Our studies suggest IL-10 as a critical regulator of airway inflammation, and IL-10 might prove a new therapeutic approach to limiting airway inflammation. Lastly, although cell clearance and anti-inflammatory cytokine production by professional phagocytes have long been studied, the relative importance of cell clearance by non-professional phagocytes under physiological settings is still limited. These data suggest that airway epithelial cells can be both phagocytic and modulate the cytokine milieu to limit airway inflammation.
METHODS SUMMARY
Mice. Rac1 fl/fl mice were crossed with CCSP-rtTA / tetO -Cre mice 18 and Rac1 deletion induced by doxycycline (1 mg ml 21 ) in drinking water. To track the Rac1-deleted airway epithelial cells specifically, the CCSP-Cre/Rac1 fl/fl were crossed with the Rosa26 STOP-EYFP reporter mice (JaxMice). Induction of airway inflammation. Mice were primed intranasally with lowendotoxin HDM extract (10 mg in 50ml volume, Indoor Biotechnologies), or chicken Ova (20 mg) on days 0, 3, 5. Control mice received saline during the priming and challenge phases. Mice were challenged intranasally on days 10, 12 and 14, and analysed for Th2 cell-dependent airway inflammation on day16. Control or CCSP-Cre/Rac1 fl/fl mice were treated intranasally for 24 h with 10 mg of HDM or 5 million to 10 million apoptotic ultraviolet-treated Jurkat cells or etoposide-treated (100 mM) BEAS-2B cells. BAL fluid was collected (24 h) and cytokine production analysed by enzyme-linked immunosorbent assay (ELISA). In vitro engulfment assay. MLE-12, BEAS-2B cells or primary airway epithelial cell cultures were plated at a density of 3 3 10 5 in a 12-well plate and incubated with 3 3 10 6 CypHer5 or TAMRA-labelled apoptotic Jurkat T-cells or etoposide (100 mM)-treated apoptotic BEAS-2B for 4 h.
